Davis's Drug Guide
momelotinib
General
High Alert Medication: This medication bears a heightened risk of causing significant patient harm when it is used in error.
Pronunciation:
moe-me-loe-ti-nib
Trade Name(s)
- Ojjaara
Ther. Class.
Pharm. Class.
kinase inhibitors
There's more to see -- the rest of this topic is available only to subscribers.
Citation
Vallerand, April Hazard., and Cynthia A. Sanoski. "Momelotinib." Davis's Drug Guide, 20th ed., F.A. Davis Company, 2026. Nursing Central, nursing.unboundmedicine.com/nursingcentral/view/Davis-Drug-Guide/3580067/6/momelotinib.
Vallerand AHA, Sanoski CAC. Momelotinib. Davis's Drug Guide. F.A. Davis Company; 2026. https://nursing.unboundmedicine.com/nursingcentral/view/Davis-Drug-Guide/3580067/6/momelotinib. Accessed June 27, 2026.
Vallerand, A. H., & Sanoski, C. A. (2026). Momelotinib. In Davis's Drug Guide (20th ed.). F.A. Davis Company. https://nursing.unboundmedicine.com/nursingcentral/view/Davis-Drug-Guide/3580067/6/momelotinib
Vallerand AHA, Sanoski CAC. Momelotinib [Internet]. In: Davis's Drug Guide. F.A. Davis Company; 2026. [cited 2026 June 27]. Available from: https://nursing.unboundmedicine.com/nursingcentral/view/Davis-Drug-Guide/3580067/6/momelotinib.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - momelotinib
ID - 3580067
A1 - Sanoski,Cynthia A,
AU - Vallerand,April Hazard,
BT - Davis's Drug Guide
UR - https://nursing.unboundmedicine.com/nursingcentral/view/Davis-Drug-Guide/3580067/6/momelotinib
PB - F.A. Davis Company
ET - 20
DB - Nursing Central
DP - Unbound Medicine
ER -
